Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. 1996 Aug 15; 98(4): 1063–1068.
PMCID: PMC507523

Role of aldosterone in the remnant kidney model in the rat.


The renin-angiotensin-aldosterone system (RAAS) participates in the injury sustained by the remnant kidney. Our studies assessed the importance of aldosterone in that model and the response of aldosterone to drugs interfering with the RAAS. Initially, four groups of rats were studied: SHAM-operated rats, untreated remnant rats (REM), REM rats treated with losartan and enalapril (REM AIIA), and REM AIIA rats infused with exogenous aldosterone (REM AIIA + ALDO). The last group was maintained with aldosterone levels comparable to those in untreated REM rats by constant infusion of exogenous aldosterone. REM rats had larger adrenal glands and a > 10-fold elevation in plasma aldosterone compared to SHAM. REM AIIA rats demonstrated significant suppression of the hyperaldosteronism as well as marked attenuation of proteinuria, hypertension, and glomerulosclerosis compared to REM. REM AIIA + ALDO rats manifested greater proteinuria, hypertension, and glomerulosclerosis than REM AIIA rats. Indeed, by 4 wk of observation all of these features of the experimental disease were similar in magnitude in REM AIIA + ALDO and untreated REM. In separate REM rats spironolactone administration did not reduce glomerular sclerosis but did transiently reduce proteinuria, lowered arterial pressure, and lessened cardiac hypertrophy. In summary, aldosterone contributes to hypertension and renal injury in the remnant kidney model.

Full Text

The Full Text of this article is available as a PDF (147K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Rosenberg ME, Smith LJ, Correa-Rotter R, Hostetter TH. The paradox of the renin-angiotensin system in chronic renal disease. Kidney Int. 1994 Feb;45(2):403–410. [PubMed]
  • Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest. 1986 Jun;77(6):1993–2000. [PMC free article] [PubMed]
  • Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest. 1992 Sep;90(3):766–771. [PMC free article] [PubMed]
  • Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993 Nov 11;329(20):1456–1462. [PubMed]
  • Martin RS, Jones WJ, Hayslett JP. Animal model to study the effect of adrenal hormones on epithelial function. Kidney Int. 1983 Sep;24(3):386–391. [PubMed]
  • Baba K, Doi Y, Franco-Saenz R, Mulrow PJ. Mechanisms by which nephrectomy stimulates adrenal renin. Hypertension. 1986 Nov;8(11):997–1002. [PubMed]
  • MORRISON AB. Experimentally induced chronic renal insufficiency in the rat. Lab Invest. 1962 Apr;11:321–332. [PubMed]
  • Hené RJ, Boer P, Koomans HA, Mees EJ. Plasma aldosterone concentrations in chronic renal disease. Kidney Int. 1982 Jan;21(1):98–101. [PubMed]
  • Berl T, Katz FH, Henrich WL, de Torrente A, Schrier RW. Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure. Kidney Int. 1978 Sep;14(3):228–235. [PubMed]
  • Reams GP, Bauer JH. Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction. Arch Intern Med. 1986 Nov;146(11):2145–2148. [PubMed]
  • Walker WG. Hypertension-related renal injury: a major contributor to end-stage renal disease. Am J Kidney Dis. 1993 Jul;22(1):164–173. [PubMed]
  • Quan ZY, Walser M, Hill GS. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int. 1992 Feb;41(2):326–333. [PubMed]
  • Purkerson ML, Hoffsten PE, Klahr S. Pathogenesis of the glomerulopathy associated with renal infarction in rats. Kidney Int. 1976 May;9(5):407–417. [PubMed]
  • Purkerson ML, Tollefsen DM, Klahr S. N-desulfated/acetylated heparin ameliorates the progression of renal disease in rats with subtotal renal ablation. J Clin Invest. 1988 Jan;81(1):69–74. [PMC free article] [PubMed]
  • Olson JL. Role of heparin as a protective agent following reduction of renal mass. Kidney Int. 1984 Feb;25(2):376–382. [PubMed]
  • Ruilope LM, Miranda B, Morales JM, Rodicio JL, Romero JC, Raij L. Converting enzyme inhibition in chronic renal failure. Am J Kidney Dis. 1989 Feb;13(2):120–126. [PubMed]
  • Pitt B. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther. 1995 Feb;9(1):145–149. [PubMed]
  • Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med. 1992 Dec;120(6):893–901. [PubMed]
  • Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest. 1994 Jun;93(6):2578–2583. [PMC free article] [PubMed]
  • Cowley AW., Jr Long-term control of arterial blood pressure. Physiol Rev. 1992 Jan;72(1):231–300. [PubMed]
  • Onoyama K, Bravo EL, Tarazi RC. Sodium, extracellular fluid volume, and cardiac output changes in the genesis of mineralocorticoid hypertension in the intact dog. Hypertension. 1979 May-Jun;1(3):331–336. [PubMed]
  • Pan YJ, Young DB. Experimental aldosterone hypertension in the dog. Hypertension. 1982 Mar-Apr;4(2):279–287. [PubMed]
  • Daniels BS, Hostetter TH. Adverse effects of growth in the glomerular microcirculation. Am J Physiol. 1990 May;258(5 Pt 2):F1409–F1416. [PubMed]
  • Lax DS, Benstein JA, Tolbert E, Dworkin LD. Effects of salt restriction on renal growth and glomerular injury in rats with remnant kidneys. Kidney Int. 1992 Jun;41(6):1527–1534. [PubMed]
  • Smith JM, Jones AW. Calcium antagonists inhibit elevated potassium efflux from aorta of aldosterone-salt hypertensive rats. Hypertension. 1990 Jan;15(1):78–83. [PubMed]
  • Larivière R, Thibault G, Schiffrin EL. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension. 1993 Mar;21(3):294–300. [PubMed]
  • Ullian ME, Schelling JR, Linas SL. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension. 1992 Jul;20(1):67–73. [PubMed]
  • Dworkin LD, Hostetter TH, Rennke HG, Brenner BM. Hemodynamic basis for glomerular injury in rats with desoxycorticosterone-salt hypertension. J Clin Invest. 1984 May;73(5):1448–1461. [PMC free article] [PubMed]
  • Wakisaka M, Spiro MJ, Spiro RG. Synthesis of type VI collagen by cultured glomerular cells and comparison of its regulation by glucose and other factors with that of type IV collagen. Diabetes. 1994 Jan;43(1):95–103. [PubMed]
  • Todd-Turla KM, Schnermann J, Fejes-Tóth G, Naray-Fejes-Tóth A, Smart A, Killen PD, Briggs JP. Distribution of mineralocorticoid and glucocorticoid receptor mRNA along the nephron. Am J Physiol. 1993 May;264(5 Pt 2):F781–F791. [PubMed]
  • Wehling M, Christ M, Theisen K. Membrane receptors for aldosterone: a novel pathway for mineralocorticoid action. Am J Physiol. 1992 Nov;263(5 Pt 1):E974–E979. [PubMed]
  • Wehling M, Käsmayr J, Theisen K. Rapid effects of mineralocorticoids on sodium-proton exchanger: genomic or nongenomic pathway? Am J Physiol. 1991 May;260(5 Pt 1):E719–E726. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem Compound links
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...